Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got big news on a gene therapy for Huntington’s disease, so let’s get straight to it.

Uniqure hails ‘groundbreaking’ results in gene therapy trial in Huntington’s disease

An experimental gene therapy from Uniqure slowed the progression of Huntington’s disease by 75% after three years — study results reported this morning that are likely to support the first approval of a genetic treatment for the rare neurodegenerative condition.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page